Background: Long-term data on the influence of smoking on risk of microscopic colitis are limited. We therefore sought to examine and characterize the association between smoking and risk of incident microscopic colitis in two large prospective cohorts of women. Methods: We conducted a prospective study of 231 015 women enrolled in the Nurses' Health Study [NHS] and NHSII. Information regarding smoking, other lifestyle factors and medications were collected biennially from 1976 to 2012 in NHS and from 1989 to 2013 in NHSII. Incident cases of microscopic colitis were confirmed through physician medical record review. We used Cox proportional hazards modelling to examine the association between smoking and risk of microscopic colitis. Results: We documented 166 incident cases of microscopic colitis over 6 122 779 person-years of follow up. Compared to non-smokers, the multivariable-adjusted hazard ratio [HR] for microscopic colitis was 2.52 (95% confidence interval [CI] 1.59-4.00) amongst current smokers and 1.54 [95% CI 1.09-2.17] amongst past smokers. The risk increased with higher pack-years of smoking [p trend = 0.001] and diminished following smoking cessation [p trend = 0.017]. Current smoking appeared to be more strongly associated with risk of collagenous colitis [HR 3.68; than lymphocytic colitis [HR 1.71;. Conclusion: In two large prospective cohort studies, we observed an association between current smoking and risk of microscopic colitis. Risk of microscopic colitis appeared to increase with higher pack-years and diminish following smoking cessation. Future studies focused on characterizing the biological mechanisms underlying these associations are warranted.
Introduction
Microscopic colitis is a debilitating and increasingly recognized inflammatory disorder of the large intestine, characterized by an increased number of intraepithelial lymphocytes in the colon with or without expansion of collagen fibres in the lamina propria. 1 In contrast to inflammatory bowel disease [IBD] , mucosal abnormalities are rarely observed in microscopic colitis. 2 Nevertheless, the incidence and prevalence of the disease have been rising over the past three decades. 1, 3 Despite the significant morbidity associated with the disease, data on potential aetiological factors are sparse.
Smoking, through its effect on the gut microbiota, mucosal barrier functions and microvasculature, is widely thought to be associated with an increased risk of Crohn's disease while exerting a protective effect on the risk of ulcerative colitis. [4] [5] [6] However, there are limited data on the link between smoking and microscopic colitis. Studies that have examined the association between smoking and risk of microscopic colitis are few, and are limited by their retrospective or case control design, [7] [8] [9] limited ascertainment of exposures, 7, 8, [10] [11] [12] [13] and use of historical data or hospital-based cohorts to define smoking prevalence amongst controls, 8, 10 therefore increasing the risk of exposure misclassification and recall bias. Furthermore, no prior study has prospectively examined the long-term impact of intensity of smoking or smoking cessation on microscopic colitis. We therefore propose to investigate these associations in two large prospective cohorts of US women.
Methods

Study population
The Nurses' Health Study [NHS] is a prospective cohort study established in 1976 when 121 700 female nurses aged 30-55 years residing in 11 US states returned mailed health questionnaires. The NHSII is a similar prospective cohort study established in 1989 with a mailed questionnaire to 116 686 female nurses aged 25-42 years. For both cohorts, follow-up questionnaires regarding medical and lifestyle information have been mailed every 2 years with a greater than 90% response rate. For this study, follow up was through the 2012 questionnaire for NHS and 2013 questionnaire for NHSII. At baseline, we excluded participants who reported a history of IBD or cancer [except for non-melanoma skin cancer], or did not provide information on smoking at baseline. This study was approved by the Partners HealthCare Institutional Review Board.
Assessment of smoking
We have previously detailed our assessment of smoking in the NHS and NHSII cohorts. 14, 15 Briefly, in baseline questionnaires, 1976 for NHS and 1989 for NHSII, participants were asked to provide information about their smoking status [current or past], the number of cigarettes smoked per day [either current or at the time they last smoked if previous smokers] and the age at which they started smoking. Follow-up biennial questionnaires asked participants to update their smoking status and the number of cigarettes smoked per day [either current or at the time they last smoked]. Number of cigarettes per day was also queried in categories ['1 to 4', ' 
Ascertainment of cases
In both cohorts, a diagnosis of microscopic colitis was obtained through self-report on the general questionnaire and validated through physician medical record review. In brief, since 1976 in NHS and 1989 in NHSII, participants have reported diagnoses of IBD, including Crohn's disease, ulcerative colitis and microscopic colitis, through open-ended response on biennial surveys. In addition, a diagnosis of IBD has been specifically queried since 1982 in NHS and 1991 in NHSII. When a diagnosis was reported on any biennial questionnaire, a supplementary questionnaire was sent asking participants specifically for diagnoses of Crohn's disease, ulcerative colitis or microscopic colitis. Related medical records were requested and reviewed by two gastroenterologists blinded to exposure information.
We excluded participants who subsequently denied the diagnosis of microscopic colitis on the supplementary questionnaire or declined permission to review their records. Data were extracted on laboratory findings, microbiology studies [e.g. stool studies], endoscopic findings and histopathology. Confirmation of all cases was based on two-physician review of histopathology records confirming a pathologist diagnosis of microscopic colitis. Information on type of microscopic colitis, namely lymphocytic colitis and collagenous colitis, were also obtained when available.
Of 241 reports of microscopic colitis, we confirmed 166 [69%] incident cases through follow up after medical record review. Of these, 154 cases had pathology reports that contained enough histological detail to discriminate between subtypes of collagenous colitis [n = 78] and lymphocytic colitis [n = 76]. The remaining 12 histopathology records stated a diagnosis of 'microscopic colitis' without further detail.
Statistical analysis
Participants began to accrue person-time of follow-up beginning at the date of return of their baseline questionnaire through to the date of diagnosis of microscopic colitis, death, last returned questionnaire or end of follow-up, whichever came first. We observed no heterogeneity in the association of smoking and risk of microscopic colitis in separate analyses of NHS and NHSII [p for heterogeneity > 0.50]. Thus, we pooled individual-level data from NHS and NHSII and adjusted for cohort in all analyses.
For our primary analysis, we used age-adjusted and multivariable-adjusted Cox proportional hazards modelling with time-varying exposure and covariate data to determine the hazard ratio [HR] and 95% confidence interval [CI] for microscopic colitis according to smoking status. We included age [months], cohort, BMI, oral contraceptive use, menopausal hormone therapy use and diabetes as covariates in the multivariable model. As NSAID use was not queried until 1990 in NHS, we performed a sensitivity analysis limiting our follow up to after 1990 in NHS and 1989 in NHSII when NSAID information was available. We also performed a sensitivity analysis limiting our follow up to after 2000, when other medications, including PPIs, SSRIs, beta blockers, ACEIs, statins and diuretics, were consistently available.
For secondary analyses, we performed age-adjusted and multivariable-adjusted Cox proportional hazards analysis to evaluate the relationship between pack-years [cumulative exposure] of smoking and time since cessation and risk of microscopic colitis. Missing exposure values for pack-years and time since smoking cessation were present in ≤ 1% of ever smokers and were set to the median values for ever smokers. We used the median value for each category of pack-years and ordinal categories of years since smoking cessation to evaluate for significance of linear trends. We additionally evaluated the association between smoking and microscopic colitis according to strata defined by cohort, BMI and NSAID use, and evaluated for potential interactions using cross-classified categories of these risk factors and smoking. We tested the significance of interactions by using the log-likelihood ratio test comparing the model with cross-classified categories with a model that included these factors as independent variables. We tested for the proportional hazards assumption by examining the interaction between age in categories and smoking variables and observed no violations [all p > 0.65]. A two-sided p-value < 0.05 was considered statistically significant. All analyses were done using SAS 9.4.
Results
Amongst 231 015 women, we documented 166 incident cases of microscopic colitis over 6 122 779 person-years of follow up. The baseline characteristics of women according to smoking status are presented in Table 1 . At baseline, 54.5% of participants were non-smokers, 22.3% were former smokers and 23.2% were current smokers. Compared to never users, current smokers were more likely to be post-menopausal and regular users of NSAIDs, and less likely to be taking oral contraceptives. Baseline characteristics of participants according to age, BMI and menopausal hormone therapy were similar according to smoking status. Figure 1 demonstrates the age-related incidence rate of collagenous colitis and lymphocytic colitis in the NHS and NHSII, as compared to cohorts from Örebro, Sweden; 22 Somme, France; 23 the Netherlands; 24 Iceland; 25 Terrassa, Spain; 26 and Olmstead County, Minnesota. 3, 27 The incidence rate of microscopic colitis rose steadily from 1/100 000 person-years in women aged 40-49.9 years to 9/100 000 person-years in women aged ≥ 80 years, similar to that described in many European cohorts, [22] [23] [24] 28 but lower than that described in some North American cohorts. 3, 27, 29 The mean age of microscopic colitis in this cohort was 64. We examined the risk of microscopic colitis according to intensity of smoking defined by pack-years of use and observed a statistically significant trend [p trend = 0.001; We also examined the relationship between smoking cessation and risk of microscopic colitis among ever smokers and observed that the risk declined significantly over time [p trend = 0.017; We explored the association between smoking and risk of microscopic colitis according to different subtypes of microscopic colitis, collagenous colitis and lymphocytic colitis. While current smoking was associated with an increased risk of collagenous colitis, we did not observe a statistically significant association between smoking and risk of lymphocytic colitis [ Table 3 ]. As compared to never smokers, the multivariable-adjusted HR of collagenous colitis was 1 As NSAID use has been widely implicated as a risk factor for microscopic colitis, we first performed a sensitivity analysis restricting our follow up to after 1990 in NHS and 1989 in NHSII when information on NSAID intake was also available. Compared to never smokers, the multivariable-adjusted HR for microscopic colitis was 1. 50 We also considered the possibility that other medications previously shown to be associated with risk of microscopic colitis may at least in part explain our observed association and therefore performed a sensitivity analysis restricting our follow up to after 2000 in NHS and 2001 in NHSII, when these medications were both available in the US and were consistently ascertained in our cohorts. Compared to never smokers, the multivariable-adjusted HRs for microscopic colitis were 1. 49 We considered the possibility that our observed associations may be due to differential health-seeking behaviours amongst women according to smoking status. Therefore, we examined the association between smoking and microscopic colitis amongst women who reported an annual physical examination in their last followup questionnaire and observed similar findings. Compared to never smokers, the multivariable-adjusted HRs of microscopic colitis were 1. 55 
Discussion
In two large prospective cohorts of US women, we demonstrated a positive association between smoking and risk of microscopic colitis. The risk of microscopic colitis appeared to increase with higher pack-years of smoking. Although risk persisted for women who stopped smoking within 5 years, women who quit smoking for more than 5 years had an attenuated risk. In addition, our data suggest a stronger association between smoking and the collagenous colitis subtype of microscopic colitis as compared to lymphocytic colitis.
Our findings regarding the impact of smoking on the rate of incident microscopic colitis are consistent with prior studies. Vigren and colleagues demonstrated higher rates of smoking amongst collagenous colitis cases compared to the general population (37% vs 17%, odds ratio [OR] = 2.95). 10 Other case-control studies have shown an increased risk of both collagenous and lymphocytic colitis with active smoking. 8 of smoking amongst patients with collagenous colitis compared to lymphocytic colitis. 7 Nevertheless, many of these studies were limited by a lack of detailed information on many potential risk factors for microscopic colitis, including BMI and NSAID or other medication use. 8, 10, 11 Through rigorous sensitivity analyses accounting for other medications associated with microscopic colitis, we demonstrate that the association between smoking and microscopic colitis is independent of that explained by use of PPIs, SSRIs, ACEIs, diuretics, beta-blockers or NSAIDs. Additionally, in our cohort, consistent with prior studies, PPIs, diuretics and SSRIs are independently associated with risk of microscopic colitis.
2,9,30-42 Furthermore, our long-term prospective cohort study adds novel data regarding the impact of cumulative tobacco exposure and smoking cessation on risk of microscopic colitis, demonstrating that while increased total dose of smoking is associated with an increased risk of microscopic colitis, this risk may be mitigated over time with smoking cessation. Therefore, our study, in addition to better characterizing the association between smoking and microscopic colitis, greatly expands upon prior studies examining this relationship. The exact mechanism underlying the association between smoking and microscopic colitis remains largely unknown. Nevertheless, several plausible mechanisms regarding the role of smoking exist, including modification of human gut microbiota, regulation of immune function and modification of epithelial barrier function. Similar mechanisms have been proposed for the previously observed positive association between smoking and increased risk of incident Crohn's disease, another chronic inflammatory disorder of the gastrointestinal tract. 5, 6, [43] [44] [45] [46] [47] Further studies may provide novel connections in the pathogenesis of these two inflammatory bowel diseases.
Our observation that smoking is particularly associated with an increased risk of collagenous colitis is biologically plausible. The pathogenesis of collagenous colitis appears to be related to myofibroblast dysfunction 48 and fibrolysis imbalance, 49 either as a primary process or as a response to microbiome changes or underlying lymphocytic infiltration. [50] [51] [52] Indeed, there is increased expression of transforming growth factor-beta [TGF-β] and tissue inhibitor of metalloproteinase-1 [TIMP-1], important regulators of extracellular matrix breakdown and fibrosis, in the colonic mucosa of patients with collagenous colitis as compared to healthy controls. 49, 53 The hypothesis that fibrosis may occur as a reaction to underlying inflammatory or microbiome changes is supported by rat models of chronic colitis, in which colonic inoculation of anaerobic bacterial strains led to upregulation of TGF-β and an increase in collagen deposition. 52 Smoking has been associated with dysbiosis in Crohn's disease, 5, 47, 54 and thus may also contribute to pathogenesis of collagenous colitis through its effect on the microbiome. Interestingly, smoking has also been shown to directly upregulate TGF-β and TIMP-1 in chronic obstructive pulmonary disease and pulmonary fibrosis, which in turn lead to fibrosis and airway remodelling. [55] [56] [57] [58] [59] Smoking may alternatively have a similar effect in the large intestine and therefore play a key role in the pathogenesis of collagenous colitis. By either reactive upregulation of TGF-β or direct myofibroblast dysfunction, an increase in TGF-β and fibrinogenesis promoted by smoking may be responsible for the disproportionate association of smoking with collagenous colitis as compared to lymphocytic colitis.
Our study has several strengths. First, we utilized two large cohorts with prospective collection of detailed smoking exposure data for over 35 years to assess the relationship between smoking and microscopic colitis. Second, detailed and updated smoking exposure data allowed us to assess intensity of smoking and influence of smoking cessation to add novel, temporal characterization of these exposures with microscopic colitis. Third, outcomes were confirmed by medical record review by two physicians, an advantage over studies that used diagnostic coding to ascertain outcomes. Furthermore, > 90% survey response rates in this cohort 60 and ability to adjust for numerous confounders through prospectively collected, detailed, time-varying covariate data minimized the biases that are typically observed in case control and retrospective studies.
Our study has several limitations that are worth noting. Although this was a large, nationwide prospective cohort study, the majority of participants in our cohort were white women, possibly limiting the generalizability of our findings. However, previous studies have demonstrated that the risk of microscopic colitis is highest amongst women, 1,61,62 making our cohorts ideal populations to study risk factors for microscopic colitis. Although it is one of the largest longitudinal studies of microscopic colitis conducted, we did rely on self-report to initially ascertain outcomes, with confirmation by physician medical record review. As such, some cases of microscopic colitis may have been missed, either due to under-reporting or absence of colonoscopy performed for symptoms. However, all participants in this study were health professionals, increasing their likelihood of accurately reporting a medical diagnosis. In addition, such outcome misclassification would probably have biased our effect estimates toward the null. Lastly, our results were consistent across numerous sensitivity analyses.
In sum, this is the first prospective cohort study to confirm the previously reported association between smoking and risk of incident microscopic colitis and further characterize the relationship by examining the impact of intensity, duration and cessation of smoking on the risk. Further studies are required to understand the mechanistic basis for the association of smoking and microscopic colitis. 
